Your browser doesn't support javascript.
Anti-inflammatory therapy for COVID-19 infection: the case for colchicine.
Reyes, Aaron Z; Hu, Kelly A; Teperman, Jacob; Wampler Muskardin, Theresa L; Tardif, Jean-Claude; Shah, Binita; Pillinger, Michael H.
  • Reyes AZ; Internal Medicine, New York University Grossman School of Medicine, New York, New York, USA.
  • Hu KA; Internal Medicine, New York University Grossman School of Medicine, New York, New York, USA.
  • Teperman J; Internal Medicine, New York University Grossman School of Medicine, New York, New York, USA.
  • Wampler Muskardin TL; Colton Center for Autoimmunity, Department of Medicine and Pathology, New York University School of Medicine, New York, New York, USA.
  • Tardif JC; Rheumatology/Medicine, New York University Grossman School of Medicine, New York, New York, USA.
  • Shah B; Montreal Heart Institute, Montreal, Québec, Canada.
  • Pillinger MH; Cardiology/Medicine, New York University Grossman School of Medicine, New York, New York, USA.
Ann Rheum Dis ; 80(5): 550-557, 2021 05.
Article in English | MEDLINE | ID: covidwho-968958
Semantic information from SemMedBD (by NLM)
1. Anti-Inflammatory Agents INTERACTS_WITH colchicine
Subject
Anti-Inflammatory Agents
Predicate
INTERACTS_WITH
Object
colchicine
2. contextual factors PROCESS_OF Outpatients
Subject
contextual factors
Predicate
PROCESS_OF
Object
Outpatients
3. COVID-19 CAUSES Hospitalization
Subject
COVID-19
Predicate
CAUSES
Object
Hospitalization
4. Anti-Inflammatory Agents INTERACTS_WITH colchicine
Subject
Anti-Inflammatory Agents
Predicate
INTERACTS_WITH
Object
colchicine
5. contextual factors PROCESS_OF Outpatients
Subject
contextual factors
Predicate
PROCESS_OF
Object
Outpatients
6. COVID-19 CAUSES Hospitalization
Subject
COVID-19
Predicate
CAUSES
Object
Hospitalization
ABSTRACT
The search for effective COVID-19 management strategies continues to evolve. Current understanding of SARS-CoV-2 mechanisms suggests a central role for exaggerated activation of the innate immune system as an important contributor to COVID-19 adverse outcomes. The actions of colchicine, one of the oldest anti-inflammatory therapeutics, target multiple mechanisms associated with COVID-19 excessive inflammation. While many COVID-19 trials have sought to manipulate SARS-CoV-2 or dampen the inflammatory response once patients are hospitalised, few examine therapeutics to prevent the need for hospitalisation. Colchicine is easily administered, generally well tolerated and inexpensive, and holds particular promise to reduce the risk of hospitalisation and mortality due to COVID-19 in the outpatient setting. Successful outpatient treatment of COVID-19 could greatly reduce morbidity, mortality and the demand for rare or expensive care resources (front-line healthcare workers, hospital beds, ventilators, biological therapies), to the benefit of both resource-replete and resource-poor regions.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Colchicine / COVID-19 / Anti-Inflammatory Agents Type of study: Prognostic study Limits: Humans Language: English Journal: Ann Rheum Dis Year: 2021 Document Type: Article Affiliation country: Annrheumdis-2020-219174

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Colchicine / COVID-19 / Anti-Inflammatory Agents Type of study: Prognostic study Limits: Humans Language: English Journal: Ann Rheum Dis Year: 2021 Document Type: Article Affiliation country: Annrheumdis-2020-219174